Another Unbelievable Month for Sarepta

David Williamson and Max Macaluso, Ph.D., The Motley Fool
Updated

Pharmaceutical company Sarepta (NAS: SRPT) was up another 26% for November, adding to its mind-boggling gains totaling 550% for the year. Its Duchenne muscular dystrophy drug Eteplirsen has actually increased the distance patients with the disease can walk in clinical trials, rather than only slowing the disease's progression, and may represent a fundamental milestone in our treatment of the disease from now on. November's big price driver for the company was Piper Jaffray's upgrade of the company, pegging it for the near term at a target price range of $60 to $80 and saying the stock could reach as high as $160. Because this is a biotech stock with its hopes pinned solely on a single drug still in the testing phase, however, this is an investment that only those with a high tolerance for risk should pursue.

See more in the following video.


While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Another Unbelievable Month for Sarepta originally appeared on Fool.com.

David Williamson has no positions in the stocks mentioned above. Follow him on Twitter, @MotleyDavid. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline and Vertex Pharmaceuticals. Motley Fool newsletter services recommend GlaxoSmithKline and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement